Filana Therapeutics Adds Jill Quigley to Board
The biotech company named a veteran industry executive to its board as it prepares a Phase 2a study of simufilam in TSC-related epilepsy.
Updated on Nov. 11, 2026 in Biotech
Filana Therapeutics, a biotechnology company developing therapies for TSC-related epilepsy, appointed Jill M. Quigley to its Board of Directors. The announcement was made from Austin, Texas.
Why it matters
The appointment adds a board member with more than 20 years of biotechnology leadership experience as the company advances toward clinical testing. Board additions with operational and commercial backgrounds can support a company moving from preclinical work into patient studies.
Filana plans to begin patient screening for a Phase 2a study of simufilam in TSC-related epilepsy by the first quarter of 2027. The announcement did not provide trial enrollment size or endpoints.
The players
Filana Therapeutics
Filana Therapeutics is a biotechnology company focused on developing therapies for TSC-related epilepsy, trading on Nasdaq under the ticker FLNA.
Jill M. Quigley
Jill M. Quigley is a biotechnology executive with more than 20 years of industry leadership experience who previously led Genuiti Therapeutics and served as COO of Passage Bio.
The details
Filana Therapeutics announced that Jill M. Quigley has joined its Board of Directors. Quigley currently serves as CEO of a preclinical biotechnology company and previously held roles including CEO of Genuiti Therapeutics and COO of Passage Bio, along with board seats at Terns Pharmaceuticals and Chemomab Therapeutics.
Timeline
November 2018: Quigley became Chief Operating Officer at Passage Bio.
September 2023: Quigley began serving as CEO of Genuiti Therapeutics.
June 2025: Quigley's tenure as CEO of Genuiti Therapeutics ended.
November 2025: Quigley began as Entrepreneur in Residence at J.P. Morgan Life Sciences Private Capital.
November 11, 2026: Filana announced Quigley's board appointment.
Roadmap
Filana is positioning simufilam for a Phase 2a study in TSC-related epilepsy, a rare genetic condition with limited treatment options. The board addition comes as the company moves toward first patient screening by early 2027.
For patients with TSC-related epilepsy, the company's progress toward a Phase 2a study represents a step toward potential future treatment options, though no timeline for approval is set. The board appointment itself has no direct effect on consumers or patients today.
The takeaway
Board additions with operational backgrounds often signal a company preparing to move from development into clinical execution. Readers following TSC-related epilepsy research can track Filana's Phase 2a screening milestone expected by early 2027.
What happens next
Filana Therapeutics plans to begin patient screening for its Phase 2a clinical study of simufilam in TSC-related epilepsy by the first quarter of 2027.
Further reading
Explore more biotech coverage for context on drug development and clinical trial news.
More information
Visit the Filana Therapeutics company website for updates on its pipeline and leadership.
Source note: This article includes information reported by The Manila times.
